Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the ...

The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the drug’s pipeline-in-a-product potential. But competition looms from a rival drug taking a similar approach.

EAST HANOVER, N.J. - Novartis (Market Cap: $223.4B), a pharmaceutical giant with robust financial health according to InvestingPro metrics, has announced the FDA approval of Fabhalta (iptacopan) for ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto. MSN Pharma was given FDA approval for its ...

My brother recently passed and I have spent 7 days trying to speak with someone at AAA. I been on hold numerous times (Your call is important to us. If it were, you would answer the phone ...

In celebration of the club's 50th season in 2025, the Seattle Seahawks have launched a year-long 50th season campaign, including a commemorative logo, merchandise, a variety of fan and community ...

Ranked by Number of employees in Georgia dedicated to FinTech Showcase your company news with guaranteed exposure both in print and online Innovation Awards will honor individuals, teams and ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy. Novartis has secured a ...